Gut Health and the Microbiome: The Hidden Drivers of Obesity

MARCOANDREA GIORGI, MD

ABSTRACT

Obesity is a complex disease that spreads globally as a pandemic which affects all human activities from basic daily functions to advanced medical conditions that transform entire communities. The core factors of dietary excess and sedentary lifestyles continue to drive obesity but scientific evidence demonstrates that the gut microbiome plays a crucial role in regulating energy balance and body fat as well as metabolic wellness. High-throughput sequencing technology has transformed our understanding of this problem while showing how gut microbial communities affect nutrient absorption and host metabolism while protecting us from increased systemic inflammation. These new discoveries are emergent and promising to help us understand how to manage this complex multifactorial condition. This review examines the developing mechanisms through which gut microbes affect obesity while assessing preclinical and human study evidence and discussing potential therapeutic approaches to modify the microbiome for obesity treatment and its related conditions.

INTRODUCTION

Obesity affects over 650 million adults globally shaping our society in ways that barely one hundred years ago we thought impossible and is now a major risk factor for type 2 diabetes, cardiovascular disease, nonalcoholic fatty liver disease, and cancer; being one of the leading causes of death.[1] Traditionally, obesity has solely and mistakenly been attributed to caloric imbalance driven by high-energy diets and decreased physical activity which caused our society to start to increasingly blaming solely patients' life style choices without considering the problem from a 360-degree point of view. In fact, this way of thinking fails to fully explain an extraordinary interindividual variability in what medical providers see on a daily basis in weight gain, response to diet, or the persistence of obesity after caloric restriction.[2]

One of the most compelling developments in the last two decades is the recognition that the microorganisms colonizing the human gastrointestinal tract are in fact integral regulators of metabolism, immune function, and even behavior. This opened up a whole new field in bio-medicine driven to find more answers given the dramatic interindividual variability. Variations in the composition and diversity of the microbiome have been linked to several disease processes that afflict patients nowadays, from cancer, to obesity and several metabolic dysfunctions in both animal models and humans.[3] These observations have sparked a paradigm shift in the core views of many medical diseases: from viewing obesity solely because of lack of effort in the desire of being healthy which lead in our society to patient blaming and even at times shaming, to appreciating the role of host-microbe interactions potentially helping us to change the way we treat medical issues and patients as a whole.

This article reviews current evidence on the gut microbiome's role in obesity, highlighting key mechanistic insights, clinical observations, and translational approaches targeting the microbiome.

THE GUT MICROBIOME: AN OVERVIEW

The human gut microbiome is and extremely complex ecosystem that could be considered its own micro-universe, which includes bacteria, archaea, viruses, fungi, and protozoa, with bacteria being the most studied and with the highest potential for future research. The dominant bacterial phyla in the gut are Firmicutes and Bacteroidetes, followed by Actinobacteria and Proteobacteria.[4]

The microbiome of the human gut plays a key role for normal human well-being in general and in fact encodes functions critical for digestion of indigestible carbohydrates, production of short-chain fatty acids (SCFAs), vitamin synthesis, bile acid metabolism, and modulation of the immune system.[5] In recent years there have been advances in metagenomic sequencing both for DNA and RNA that enabled researchers to characterize the microbial communities and their metabolic capabilities in unprecedented detail, this opened the scientific world to an enormous amount of information much of which still needs to be understood to be able to be utilized clinically in a meaningful way.

EVIDENCE LINKING THE MICROBIOME TO OBESITY

Preclinical Studies

A lot of work has involved the creation of models that could be utilized to explore the microverse of microbiome interaction; specifically for obesity, germ-free (GF) mouse

models have been instrumental in demonstrating that the gut microbiome contributes to host adiposity. The hypothesis that sparked the creation of such a model is the idea of assessing how the presence of bacteria influences tissue adiposity and its metabolism. In a landmark study, Bäckhed et al showed that GF mice colonized with microbiota from conventionally raised animals exhibited a 60% increase in body fat despite reduced food intake, suggesting enhanced energy harvest by the microbiota and a key role in determining body weight.[6] This effect was further supported by Turnbaugh et al, who transplanted microbiota from genetically obese (ob/ob) mice into GF mice, which then developed significantly greater fat mass than mice colonized with microbiota from lean controls suggesting the key role of gut bacteria yet again.[3]

Subsequent animal models have identified specific microbial metabolic pathways that link gut bacteria to host energy balance; this was seen as a step forward by not looking at the specific bacteria, but how the product of its metabolism affected weight metabolism. One of the main mechanisms was found to involve the fermentation of non-digestible carbohydrates into short-chain fatty acids (SCFAs): primarily acetate, propionate, and butyrate, that were produced for the most part in the colon. SCFAs were found to serve as both nutrients and interestingly also as signaling molecules, which were hypothesized to have a role in regulating host appetite with promising clinical implications, lipid metabolism, as well as insulin sensitivity.[12–14]

Surprisingly though, certain studies have shown that even obese mice do exhibit increased levels of SCFAs in feces, which challenged the idea that they serve as protective factors, since other authors found that SCFAs were associated with having possible beneficial metabolic effects in lean animals. The different results from these studies suggested that obesity caused SCFA absorption dysfunction while altering the fermentation processes in the colon, which was confirmed by studies in both mice and humans.[23]

Leaning deeper in this metabolic pathway given its promising potential, SCFAs are found to act through receptors such as free fatty acid receptor 2 (FFAR2), which has been shown to mediate appetite-regulating hormones like GLP-1 and peptide YY (PYY). To sustain this pathway, other studies appreciated how FFAR2 knockout mice do in fact become obese, while on the other side overexpression in adipose tissue leads to more lean phenotypes. In addition, these seemingly potent metabolic effects disappear under germ-free conditions, highlighting the critical role of the microbiota in this pathway.[23]

Additional animal models have also shown that microbial metabolites such as SCFAs activate AMPK (or AMP-activated protein kinase) in liver and muscle tissues, which is a crucial enzyme that acts as a sensor of cellular energy status. AMPK is activated by conditions that lower cellular energy levels, and its activation triggers metabolic changes that promote energy production and inhibit energy-consuming processes which makes it a key player in maintaining cellular energy balance and has implications for various metabolic disorders and diseases; specifically for our purposes it improves lipid and glucose metabolism.[24]

On the other side, other studies focused on gut dysbiosis that may lead to impaired secretion of GLP-1 and PYY, resulting in increase in hunger. Mice lacking PYY exhibit in fact increased food intake and obesity, while mice with elevated PYY are resistant to diet-induced weight gain.[25]

Inflammation is another key player for weight metabolism; additional authors have found that mice with dysbiosis show elevated systemic levels of lipopolysaccharide (LPS), a pro-inflammatory endotoxin derived from gram-negative bacteria that binds to TLR4 on macrophages, triggering inflammatory cascades via NF-κB and contributing to insulin resistance and β-cell dysfunction; in fact, infusion of LPS into lean mice induces weight gain and metabolic syndrome-like features, suggesting a causal role of this molecule.[16]

These murine models not only establish causality but also offer potential targets for future therapies, including modulation of SCFA signaling pathways.

Human Observational Studies

Multiple studies in humans have associated obesity with reduced microbial diversity and altered relative abundances of bacterial taxa, and, specifically, several reports have identified imbalances in the relationship of Firmicutes-to-Bacteroidetes ratio in obese individuals compared to lean controls[8,9], suggesting a potential correlation of this potential imbalance. Important to remember that these two strains are in fact the most dominant bacterial phyla in the human gut making a large portion of the microbiome. These bacteria are respectively Gram positives and Gram negative and play a role in breaking down complex carbohydrates (Firmicutes) and fibers (Bacteroidetes) producing SCFAs. Bacteroidetes are often associated with leaner body mass and a healthier gut, as they are less efficient at extracting calories from food compared to Firmicutes. However, this observation is not universal across all cohorts; in fact there are several differences when looking at patients' geographic, dietary, and other characteristics.[10]

Inflammation also plays an important role in altering metabolic pathways and impacting SCFAs, and in many studies patients with obesity have in fact been found to have higher levels of pro-inflammatory endotoxins contributing to dysbiosis and alterations in said metabolic pathways.[11]

MECHANISMS LINKING THE MICROBIOME TO OBESITY

Enhanced Energy Harvest

The first proposed mechanism involves the microbiome's capability to enhance the extraction of calories from

indigestible polysaccharides which affects appetite and satiety and absorption; in fact, microbial fermentation generates SCFAs such as acetate, propionate, and butyrate, which can be absorbed by the host and could even contribute up to 10% of daily caloric requirements and they also function as signaling molecules affecting lipid and glucose metabolism via G-protein coupled receptors (e.g., GPR41, GPR43).[12,13]

Regulation of Lipogenesis

Acetate, the most abundant SCFA, has been implicated in promoting lipogenesis in the liver, so microbial metabolites modulate expression of genes such as acetyl-CoA carboxylase and fatty acid synthase, enhancing triglyceride accumulation contributing to weight gain.[14]

Modulation of Satiety and Appetite

The gut microbiota helps controlling satiety through SCFA production and enteroendocrine cell regulation which results in butyrate and propionate stimulating PYY and GLP-1 hormone secretion that suppress appetite and enhance insulin sensitivity.[15] In a state of dysbiosis these signals may be attenuated, favoring increase in appetite and calorie intake.

Metabolic Endotoxemia

Certain Gram-negative bacteria in the human gut produce lipopolysaccharide (LPS), which is a strong endotoxin that can lead to increased gut permeability during dysbiosis, allowing translocation of LPS into circulation, which will trigger low-grade inflammation and insulin resistance.[16] This endotoxemia has been proposed as a one of the drivers of obesity-related inflammation, activating other metabolic cascades.

Bile Acid Metabolism

Bile is an important factor in GI metabolism and absorption, and is well regulated by several hormones and stimuli. The microbiome interacts with bile acids in a continuous manner through a vital connection where gut bacteria convert primary bile acids into secondary bile acids which activate nuclear enteric cell receptors including farnesoid X receptor (FXR) and G protein-coupled bile acid receptor 1 (TGR5) to control lipid metabolism and glucose homeostasis and energy expenditure.[17]

THERAPEUTIC MODULATION OF THE MICROBIOME IN OBESITY

Given the microbiome's role in obesity, interventions aiming to restore eubiosis have attracted considerable interest, interventions range from dietary changes and the constant search of the "perfect diet" to medical treatments that have pushed the medical industry into creating a billion-dollar market with thousands of over-the-counter remedies to "restore" the microbiome.

Diet

Diet remains the most powerful modulator of the gut microbiome with the highest chance of impact, specifically high-fiber diets rich in complex carbohydrates promote SCFA-producing bacteria and microbial diversity carrying along several health benefits[18]; on the other side, Western diets high in fat and refined sugar drive dysbiosis and possibly metabolic derangements that over the years can lead not only to obesity but also to other several disease processes; many studies have in fact shown that dietary interventions can rapidly shift microbiome composition within days, emphasizing this important role.[19]

Probiotics

Probiotics are live microorganisms that are hypothesized to confer health benefits and have been historically very well tested in obesity management, especially strains including Lactobacillus and Bifidobacterium species, but unfortunately several meta-analyses suggest that probiotic supplementation modestly reduces body weight and BMI, though results are heterogeneous and strain-specific.[20]

Prebiotics

Prebiotics, such as Inulin and fructooligosaccharides, are nondigestible substrates that promote the growth of beneficial microbes which then increase SCFA production; this has been associated in certain studies to create improved glucose regulation but unfortunately still with modest weight loss.[21]

Fecal Microbiota Transplantation (FMT)

FMT is a novel technique that involves transferring stool from healthy donors to recipients to restore microbial balance. It is based on the theory of introducing a healthy person microbiome into a patient with dysbiosis hoping to restore balance, but while FMT has shown success in treating both acute and recurrent *Clostridioides difficile* infections at times resistant to antibiotic therapy, its application in obesity remains experimental. A landmark study demonstrated that FMT from lean donors improved insulin sensitivity in obese recipients, but effects on weight were inconsistent.[22]

LIMITATIONS AND FUTURE DIRECTIONS

While the association between the microbiome and obesity is compelling, several challenges remain:

- **Causality vs. Correlation:** Many studies are observational and cannot establish causality.
- **Interindividual Variability:** Microbiome composition is influenced by genetics, diet, geography, and medications.
- **Translational Gaps:** Findings in animal models may not fully translate to humans.

- **Durability of Interventions:** Microbiome shifts often revert after discontinuation of dietary or probiotic interventions.

Future research integrating multi-omics (metagenomics, metabolomics, transcriptomics) with longitudinal cohorts may clarify causal pathways and enable personalized microbiome-targeted therapies.

CONCLUSION

The gut microbiome functions as a vital system which controls host metabolic processes, inflammatory responses and energy equilibrium. While eubiosis remains the desired hallmark of a healthy gut, dysbiosis has been proven to contribute to the pathogenesis of obesity through increased energy harvest, altered gut hormone signaling, endotoxemia, and alterations of bile acid pathways. Promising microbiome-directed interventions are emerging and promising, but large-scale clinical trials are still needed to define their efficacy and durability. A deeper understanding of host-microbe interactions may ultimately yield transformative strategies to prevent and treat obesity.

References

1. World Health Organization. Obesity and overweight. 2024. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
2. Müller MJ, et al. Beyond the energy balance concept: a dynamical perspective on obesity. Obes Rev. 2018;19(1):14–23.
3. Turnbaugh PJ, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–31.
4. Qin J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65.
5. Rowland I, et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr. 2018;57(1):1–24.
6. Bäckhed F, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718–23.
7. Ridaura VK, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341(6150):1241214.
8. Ley RE, et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102(31):11070–75.
9. Turnbaugh PJ, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480–84.
10. Finucane MM, et al. A taxonomic signature of obesity in the microbiome? Getting to the guts of the matter. PLoS One. 2014;9(1):e84689.
11. Le Chatelier E, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500(7464):541–46.
12. den Besten G, et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013;54(9):2325–40.
13. Canfora EE, et al. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. 2019;15(5):261–73.
14. Perry RJ, et al. Acetate mediates a microbiome–brain–β-cell axis to promote metabolic syndrome. Nature. 2016;534(7606):213–17.
15. Chambers ES, et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut. 2015;64(11):1744–54.
16. Cani PD, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–72.
17. Joyce SA, Gahan CGM. Bile acid modifications at the microbe–host interface: potential for nutraceutical and pharmaceutical interventions in host health. Annu Rev Food Sci Technol. 2016;7:313–33.
18. Sonnenburg ED, et al. Diet-induced extinctions in the gut microbiota compound over generations. Nature. 2016;529(7585):212–15.
19. David LA, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559–63.
20. John GK, Mullin GE. The gut microbiome and obesity. Curr Oncol Rep. 2016;18(7):45.
21. Delzenne NM, et al. Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol. 2011;7(11):639–46.
22. Vrieze A, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913–16.e7.
23. Bjursell M, Admyre T, Göransson M, Marley AE, Smith DM, Oscarsson J, Bohlooly-Y M. Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am J Physiol Endocrinol Metab. 2011 Jan;300(1):E211-20. doi: 10.1152/ajpendo.00229.2010. Epub 2010 Oct 19. PMID: 20959533.
24. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011 Sep 15;25(18):1895-908. doi: 10.1101/gad.17420111. PMID: 21937710; PMCID: PMC3185962.
25. Yu M, Yu B, Chen D. The effects of gut microbiota on appetite regulation and the underlying mechanisms. Gut Microbes. 2024 Jan-Dec;16(1):2414796. doi: 10.1080/19490976.2024.2414796. Epub 2024 Nov 6. PMID: 39501848; PMCID: PMC11542600.

Author

Marcoandrea Giorgi, MD, Warren Alpert Medical School of Brown University; Brown University Health, Department of Surgery, Providence, RI.

Disclosures

Marcoandrea Giorgi serves as a consultant for BD.

Correspondence

Marcoandrea Giorgi, MD
195 Collyer St, Suite 302, Providence, RI 02904
401-793-5701
Fax 401-793-5171
mgiorgi@brownhealth.org